ClinicalTrials.gg
CompletedNCT00734565Updated Feb 8, 2012

Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

A Phase 1 interventional study of Haemophilus influenzae type b in Haemophilus Influenzae Type b, sponsored by Novartis Vaccines. Completed at 1 site in China. Open to participants aged 2 Months to 20 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-08.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
2 Months to 20 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Haemophilus Infections with a site in China — 2 open to participants now, 3 under way, none of them phase 3. Haemophilus Infections · China.

Enrollment
16th of 17
40 · median 700
Started
2008
with 1 other
Phase 1
3 of 17
1 open now
Registered
3rd of 17
by date
Lead sponsor
7 of 17
Novartis Vaccines

Among the 17 studies in Haemophilus Infections with a site in China, this one is the 16th largest by enrollment, is one of 2 that started in 2008, is one of 3 in phase 1, and was the 3rd registered.

Haemophilus Infections

176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.

Browse Haemophilus Infections studies →

Open to participants now

2 of the 17 studies in Haemophilus Infections with a site in China are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 2 Months to 20 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Haemophilus Infections with a site in China, or all of them as a file.
02

Study summary

This study will investigate safety and reactogenicity of a monovalent conjugated vaccine against Haemophilus influenzae type b in healthy children

03

Conditions studied

  • Haemophilus Influenzae Type b

Keywords

  • vaccine
  • prevention
  • haemophilus influenzae type b
  • children
04

Who can participate

Ages eligible
2 Months to 20 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants of either sex, aged 16 - 20 months / 2 - 4 months
  • in good health as determined by: medical history physical examination clinical judgment of the investigator;
  • available for all visits scheduled in the study and able to comply with all study regulations;
  • written obtained, from at least one parent or legal guardian

Exclusion criteria

Exclusion Criteria:

  • parent or legal guardian is unwilling or unable to give written to participate in study;
  • infants who presented a previous disease potentially related to Haemophilus influenzae type b;
  • infants who had household contact and/or intimate exposure in the previous 30 days to an individual with ascertained Haemophilus influenzae type b disease;
  • infants who have received any other Haemophilus influenzae type b immunization dose before (for 16-20 months old children who have received a booster vaccination already);
  • premature (before 37th week of gestation) or birth weight less than 2500 g;
  • history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or to any vaccine component;
  • fever ≥38.0 °C (axillary body temperature) and/or significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrollment;
  • subjects with any serious chronic disease such as cardiac, neurological, metabolic, hematologic, or neoplastic disease;
  • known/suspected immunodeficiency, or disease, or any immunologic disorder;
  • subjects with any neurological disorder, e.g., epilepsy or history of seizure disorder;
  • subjects with a genetic anomaly;
  • treatment with or other drugs;
  • treatment with parenteral immunoglobulin preparation, blood products, and/or plasma derivatives (or: within the past 3 months - applicable for children 16 - 20 months);
  • any vaccination administered within 2 weeks (14 days) before enrollment;
  • participation in any other trial simultaneously;
  • planned surgery during the study period;
  • any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objective
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    1

    Biological: Haemophilus influenzae type b

Interventions

  • BiologicalHaemophilus influenzae type b

    1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months

06

What researchers measure

Primary outcomes

  1. Rates of local and systemic reactions, adverse events (AEs), and serious adverse events (SAEs) after first vaccination dose will be evaluated.

    Time frame: 30 days

Secondary outcomes

  1. Rates of local and systemic reactions, adverse events (AEs), and serious adverse events (SAEs) after second vaccination dose will be evaluated.

    Time frame: 90 days

07

Study locations

1 site
  • Vaccination site
    Shijiazhuang, 050800, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2008
First posted
Aug 14, 2008
Start
Jul 2008
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Last update
Feb 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00734565
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Aug 14, 2008
Start date
Jul 2008
Primary completion
Oct 2008
Completion
Oct 2008
Last update
Feb 8, 2012

Study contacts

Novartis Vaccines
study chair · Novartis Vaccines
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion